Kandu logo

Kandu

Kandu, formed by the April 2025 merger of Neurolutions and Kandu Health, sells the FDA-cleared IpsiHand noninvasive brain-computer interface for stroke arm recovery plus remote stroke care services. LeadIQ estimates Kandu's annual revenue at about $10 million to $25 million. This is an estimate, not a reported figure.2,1,5

Robotics Reviewed Editorial TeamUpdated November 6, 2026neurolutions.com

Our take

IpsiHand is one of the few FDA-cleared noninvasive BCI therapies for chronic stroke arm recovery, which sets Kandu apart from generic rehab vendors.1

The Neurolutions and Kandu Health merger combines a device with telehealth services, so buyers evaluate both therapy hardware and care programs.2

Scores by criterion

Kandu scores out of 10
Pricing transparency3.0
Product maturity7.5
Deployment evidence7.0
Company durability7.0
Ease of integration6.0
Overall score (average of the five)6.1

Each criterion is defined on our methodology page.

Who uses Kandu and what it's for

Stroke survivors and clinicians seeking at-home BCI therapy for upper-limb recovery.1

Health systems and payers managing post-stroke readmissions and rehab outcomes.2

History

Neurolutions was founded in 2007 around BCI technology co-invented with Washington University researchers. In April 2025 it merged with Kandu Health to form Kandu, Inc., with a concurrent $30 million financing.2

Dr. Leo Petrossian, formerly Neurolutions CEO, is CEO of Kandu. Kirsten Carroll, formerly Kandu Health CEO, became general manager.4,2

IpsiHand and stroke recovery

IpsiHand is an FDA-cleared noninvasive BCI system that helps chronic stroke patients regain arm and hand function at home. The company cites more than 8 million therapy repetitions and clinical results including average Fugl-Meyer gains.1

Kandu pairs the device with remote multidisciplinary stroke support through licensed clinicians and an app.2,3

Pricing

Kandu and Neurolutions do not publish consumer list prices for IpsiHand. Access runs through clinical qualification and reimbursement pathways, including a CMS code Neurolutions previously announced.1,2

Competitive landscape

Which of these companies scores best, and who is each one built for?Hover over or tap a logo for details.
Top rated, for patients and clinicsTop rated, for large hospitalsLower score, for patients and clinicsLower score, for large hospitalsNot yet reviewed45678910Review Score← Patients and clinicsLarge hospital systems →Who it's built for6.17.06.35.9
Kandu and its competitors
CompanyProductPricing modelDeployment footprintWhere Kandu wins or loses
KanduIpsiHand FDA-cleared noninvasive BCI therapy1Merged with Kandu Health in April 2025; $30M financing2Clinical claims include Fugl-Meyer gains and millions of therapy reps1FDA-cleared noninvasive BCI for chronic stroke arm recovery
MyomoMyoPro powered arm and hand brace15Medicare fee schedule rates of $33,481 and $65,8727Patients reached through clinician referrals and orthotics and prosthetics channels8,16Myomo wins on myoelectric powered arm braces. Kandu wins on noninvasive BCI therapy.
LifewardReWalk personal exoskeleton and AlterG anti-gravity systems10Medicare fee of $91,032 for a personal exoskeleton9Individual users through Medicare and insurers; AlterG in more than 4,000 facilities9Lifeward wins on walking exoskeletons. Kandu wins on at-home BCI arm recovery.
WandercraftAtalante X and Eve self-balancing exoskeletons17Not published17Devices in more than 700 rehabilitation centers after buying Ekso18Wandercraft wins on self-balancing walking exoskeletons. Kandu wins on BCI hand therapy.
VivistimVivistim paired vagus nerve stimulation for stroke rehab14Implantable therapy sold through clinical channels14Stroke rehab clinics offering VNS therapy14Vivistim wins on implanted VNS. Kandu wins on noninvasive at-home BCI.

Limits

Patient pricing depends on clinical pathways and reimbursement, not a public cart price.1

The merged company is still integrating device and services businesses.2

Revenue is not disclosed. LeadIQ estimates about $10 million to $25 million annually for Kandu. This is an estimate, not a reported figure.5

What customers say

Where it helps

Chronic stroke patients past the usual rehab window are the primary IpsiHand fit.1

Health systems that want device plus remote care should evaluate the full Kandu offering.2

Where it falls short

Buyers seeking powered braces or walking exoskeletons should look at Myomo or Lifeward.

Leadership

Sources